<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003726</url>
  </required_header>
  <id_info>
    <org_study_id>D9815</org_study_id>
    <secondary_id>P30CA023108</secondary_id>
    <secondary_id>DMS-9815</secondary_id>
    <secondary_id>NCI-V98-1512</secondary_id>
    <nct_id>NCT00003726</nct_id>
  </id_info>
  <brief_title>Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I/II Study of Recombinant Desulfato Hirudin, Lepirudin (Refludan) in Small Cell Lung Cancer Patients Previously Treated With Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Anticoagulants, such as lepirudin, may help prevent blood clots from forming in
      patients who have received chemotherapy for small cell lung cancer.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of lepirudin in
      treating patients with recurrent or advanced small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the dose, safety, and antitumor response rate of lepirudin in
      patients with recurrent or extensive stage small cell lung cancer previously treated with
      chemotherapy.

      OUTLINE: This is a dose escalation (in individual patients) study. Patients receive dose
      escalated lepirudin subcutaneously once or twice a day for 3-4 days. Dose escalation
      continues in each patient until aPTT prolongation occurs or the maximum dose level is
      reached. The patient then continues treatment on the maximum tolerated dose. Treatment
      continues in the absence of disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 20-35 patients will be accrued for this study within 18-24
      months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study funding was dropped.
  </why_stopped>
  <start_date>November 1998</start_date>
  <completion_date type="Actual">July 2001</completion_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose, Safety and Antitumor Response Rate of Administering Recombinant Desulfato Hirudin, Elpirudin to Previously Treated Patients With Extensive or Recurrent Small Cell Lung Cancer</measure>
    <time_frame>18 months</time_frame>
    <description>Evaluated through clinical exams, tumor assessments, laboratory assessment, and adverse event assessments.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Lepirudin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 1: 10 mg once daily -&gt; (total dose, 10 mg/d) Dose level 2: 15 mg once daily -&gt; (total dose, 15 mg/d) Dose level 3: 10 mg twice daily -&gt; (total dose, 20 mg/d) Dose level 4: 15 mg twice daily -&gt; (total dose, 30 mg/d) Dose level 5. 20 mg twice daily -&gt; (total dose, 40 mg/d) Dose level 6: 25 mg twice daily -&gt; (total dose, 50 mg/d)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>lepirudin</intervention_name>
    <description>lepirudin</description>
    <arm_group_label>Lepirudin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          1. Pathologically confirmed recurrent or extensive stage small cell lung cancer.

          2. Received at least one prior chemotherapy regimen

          3. Measurable or evaluable disease that has not been irradiated

          4. No pleural effusions, bone metastases, brain metastases, elevated serum enzymes, or
             radionuclide scans as the sole indicator lesion

          5. Brain metastases allowed if patients received cranial irradiation and have no clinical
             evidence of brain metastases

        PATIENT CHARACTERISTICS:

          1. Age: Not specified

          2. Performance status: Karnofsky 60-100%

          3. Life expectancy: Not specified

          4. Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3

          5. Hepatic: Bilirubin no greater than 2.0 mg/dL PT and aPTT normal

          6. Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance greater than 60
             mL/min

          7. Cardiovascular: No unstable heart rhythm No unstable angina No clinical evidence of
             congestive heart failure No prior cerebrovascular accident or stroke No uncontrolled
             or severe hypertension

          8. Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use
             effective contraception

          9. At least 6 weeks since any signs or symptoms of bleeding No history of bleeding
             disorder

         10. No bacterial endocarditis or other active infection

        PRIOR CONCURRENT THERAPY:

          1. Biologic therapy: Not specified

          2. Chemotherapy: At least 3 weeks since prior chemotherapy

          3. Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since prior
             radiotherapy

          4. Surgery: At least 6 weeks since major surgery, trauma, or needle biopsy of any organ

          5. Other: No concurrent anticoagulant or platelet inhibitor therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James R. Rigas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norris Cotton Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2004</study_first_posted>
  <results_first_submitted>May 16, 2013</results_first_submitted>
  <results_first_submitted_qc>June 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2016</results_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lepirudin</mesh_term>
    <mesh_term>Hirudins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One participant was enrolled to the trial and started on 10mg and increased to 20mg. However developed progression of disease and was removed from the trial.</recruitment_details>
      <pre_assignment_details>Funding was pulled and therefore the trial was not completed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lepirudin</title>
          <description>Dose level 1: 10 mg once daily -&gt; (total dose, 10 mg/d) Dose level 2: 15 mg once daily -&gt; (total dose, 15 mg/d) Dose level 3: 10 mg twice daily -&gt; (total dose, 20 mg/d) Dose level 4: 15 mg twice daily -&gt; (total dose, 30 mg/d) Dose level 5. 20 mg twice daily -&gt; (total dose, 40 mg/d) Dose level 6: 25 mg twice daily -&gt; (total dose, 50 mg/d)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Funding was pulled on the trial and therefore no other participants were enrolled</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lepirudin</title>
          <description>Dose level 1: 10 mg once daily -&gt; (total dose, 10 mg/d) Dose level 2: 15 mg once daily -&gt; (total dose, 15 mg/d) Dose level 3: 10 mg twice daily -&gt; (total dose, 20 mg/d) Dose level 4: 15 mg twice daily -&gt; (total dose, 30 mg/d) Dose level 5. 20 mg twice daily -&gt; (total dose, 40 mg/d) Dose level 6: 25 mg twice daily -&gt; (total dose, 50 mg/d)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dose, Safety and Antitumor Response Rate of Administering Recombinant Desulfato Hirudin, Elpirudin to Previously Treated Patients With Extensive or Recurrent Small Cell Lung Cancer</title>
        <description>Evaluated through clinical exams, tumor assessments, laboratory assessment, and adverse event assessments.</description>
        <time_frame>18 months</time_frame>
        <population>No data were collected</population>
        <group_list>
          <group group_id="O1">
            <title>Lepirudin</title>
            <description>Dose level 1: 10 mg once daily -&gt; (total dose, 10 mg/d) Dose level 2: 15 mg once daily -&gt; (total dose, 15 mg/d) Dose level 3: 10 mg twice daily -&gt; (total dose, 20 mg/d) Dose level 4: 15 mg twice daily -&gt; (total dose, 30 mg/d) Dose level 5. 20 mg twice daily -&gt; (total dose, 40 mg/d) Dose level 6: 25 mg twice daily -&gt; (total dose, 50 mg/d)</description>
          </group>
        </group_list>
        <measure>
          <title>Dose, Safety and Antitumor Response Rate of Administering Recombinant Desulfato Hirudin, Elpirudin to Previously Treated Patients With Extensive or Recurrent Small Cell Lung Cancer</title>
          <description>Evaluated through clinical exams, tumor assessments, laboratory assessment, and adverse event assessments.</description>
          <population>No data were collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lepirudin</title>
          <description>Dose level 1: 10 mg once daily -&gt; (total dose, 10 mg/d) Dose level 2: 15 mg once daily -&gt; (total dose, 15 mg/d) Dose level 3: 10 mg twice daily -&gt; (total dose, 20 mg/d) Dose level 4: 15 mg twice daily -&gt; (total dose, 30 mg/d) Dose level 5. 20 mg twice daily -&gt; (total dose, 40 mg/d) Dose level 6: 25 mg twice daily -&gt; (total dose, 50 mg/d)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The funding of the trial was discontinued and therefore only one participant was enrolled to the trial and experienced no adverse events.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>James Rigas, MD</name_or_title>
      <organization>Dartmouth-Hitchcock Medical Center</organization>
      <phone>603-650-6344</phone>
      <email>james.r.rigas@hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

